Issue 19, 2021

Recent progress in nanotechnology-based drug carriers for celastrol delivery

Abstract

Celastrol (CLT) is an active ingredient that was initially discovered and extracted from the root of Tripterygium wilfordii. The potential pharmacological activities of CLT in cancer, obesity, and inflammatory, auto-immune, and neurodegenerative diseases have been demonstrated in recent years. However, CLT's clinical application is extremely restricted by its low solubility/permeability, poor bioavailability, and potential off-target toxicity. The advent of nanotechnology provides a solution to improve the oral bioavailability, therapeutic effects or tissue-targeting ability of CLT. This review focuses on the most recent advances, improvements, inventions, and updated literature of various nanocarrier systems for CLT.

Graphical abstract: Recent progress in nanotechnology-based drug carriers for celastrol delivery

Article information

Article type
Review Article
Submitted
23 Apr 2021
Accepted
15 Jul 2021
First published
16 Aug 2021
This article is Open Access
Creative Commons BY license

Biomater. Sci., 2021,9, 6355-6380

Recent progress in nanotechnology-based drug carriers for celastrol delivery

L. Guo, Y. Zhang and K. T. Al-Jamal, Biomater. Sci., 2021, 9, 6355 DOI: 10.1039/D1BM00639H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements